Skip to content
sellNotable cluster of 4

Hubert L Allen sold $24M of ABT

EXECUTIVE VICE PRESIDENT at ABBOTT LABORATORIES. 189,788 shares at an average of $128.26, traded Jan 29, 2025, filed Jan 31, 2025.

Warning score
60
Value
$24M
189,788 shares
Holdings after
184,806
-60% from before
From 52-week low
+15%
low $107.61, close $123.84
From 52-week high
-1%
high $125.36, as of Jan 29, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $24.3M at market
    +25
  • Share of holdings sold
    Sold 60% of holdings
    +20
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +7.9%, 3m +4.3%, 6m +0.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ABTOct 9, 2026 · close 99.60
Since filing Jan 31, 2025: -19.6%SPY +31.8% · excess -51.4%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-25-002589, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 29, 2025MOption exercise
Common shares without par value
+131,360$38.40$5.0M316,166Jan 31, 2025
Jan 29, 2025SOpen-market sale
Common shares without par value
-131,360$128.35$17M184,806Jan 31, 2025
Jan 30, 2025MOption exercise
Common shares without par value
+58,428$38.40$2.2M243,234Jan 31, 2025
Jan 30, 2025SOpen-market sale
Common shares without par value
-58,428$128.07$7.5M184,806Jan 31, 2025
Jan 29, 2025MOption exercise
Option (right to buy)derivative
-131,360$0.00$058,428Jan 31, 2025
Jan 30, 2025MOption exercise
Option (right to buy)derivative
-58,428$0.00$00Jan 31, 2025

Related signals

Other insiders at ABBOTT LABORATORIES and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
33Weak
ABTsell 2
ABBOTT LABORATORIES
John A. McCoy Jr.
VICE PRESIDENT AND CONTROLLER
$2,958
27 shares
-0%
70Notable
ABTsell 3
ABBOTT LABORATORIES
Robert B Ford
CHAIRMAN AND CEO
$46M
398,832 shares
-57%
43Moderate
ABTsell 2
ABBOTT LABORATORIES
Louis H. Morrone
EXECUTIVE VICE PRESIDENT
$643k
5,850 shares
-8%
62Notable
ABTbuy 3
ABBOTT LABORATORIES
John G Stratton
director
$174k
2,000 shares
+9%
72Notable
ABTbuy 3
ABBOTT LABORATORIES
Daniel J Starks
director
$927k
10,000 shares
+0%
75Notable
ABTbuy 3
ABBOTT LABORATORIES
Philip P Boudreau
EVP AND CFO
$201k
2,200 shares
-
40Moderate
ABTsell 6
ABBOTT LABORATORIES
Daniel Gesua Sive Salvadori
EVP AND GROUP PRESIDENT
$102k
885 shares
-1%
48Moderate
ABTsell 6
ABBOTT LABORATORIES
John A. McCoy Jr.
VICE PRESIDENT AND CONTROLLER
$68k
585 shares
-2%
48Moderate
ABTsell 6
ABBOTT LABORATORIES
Mary K Moreland
EXECUTIVE VICE PRESIDENT
$71k
613 shares
-1%
51Moderate
ABTsell 6
ABBOTT LABORATORIES
Louis H. Morrone
EXECUTIVE VICE PRESIDENT
$132k
1,144 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Hubert L Allen sold $24M of ABT | InsiderTell